We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Jacob Udell

Jacob A Udell MD, MPH, FRCPC

Assistant Professor of Medicine, Division of Cardiology, Department of Medicine, Peter Munk Cardiac Centre, Toronto General Hospital and Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada

Jacob A. Udell is a Cardiologist and Clinician-Scientist at Women’s College Hospital and the Peter Munk Cardiac Centre, Toronto General Hospital at the University of Toronto, with emerging expertise in observational studies, clinical trials, and health services research. His team’s work on innovative cardiovascular risk factor identification and therapy has led to alterations in international cardiovascular and diabetes clinical practice guidelines; and changes by the FDA in the label of glycemic therapies. Utilizing the administrative health care databases, registries, and clinical trial populations at his disposal, Dr. Udell studies the cardiovascular benefits and risks of diabetes and antiplatelet therapies and other novel therapies, including influenza vaccination. He is a co-principal investigator of the NHLBI-sponsored INVESTED randomized controlled trial, which is investigating the cardiovascular benefit of high-dose versus standard-dose influenza vaccination.

Disclosures

Disclosures: Dr. Udell reports honoraria for advisory relationships from Amgen, Boehringer-Ingelheim, Janssen, Novartis, and Sanofi Pasteur; and grants from AstraZeneca and Novartis.